Related Experiment Video
Updated: Sep 2, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Detection of Anticancer Drug-Induced Cardiotoxicity Using VCAM1-Targeted Nanoprobes
Humayra Afrin1,2, Md Nurul Huda1,2, Tamanna Islam1,2
1Environmental Science and Engineering, University of Texas at El Paso, El Paso, Texas 79965, United States.
Abstract:
Chemotherapy-induced cardiac toxicity is an undesirable yet very common effect that increases the risk of death and reduce the quality of life of individuals undergoing chemotherapy. However, no feasible methods and techniques are available to monitor and detect the degree of cardiotoxicity at an early stage. Therefore, in this project, we aim to develop a fluorescent nanoprobe to image the toxicity within the cardiac tissue induced by an anticancer drug. We have observed that vascular cell adhesion molecule 1 (VCAM1) protein alone with collagen was overly expressed within the heart, when an animal was treated with doxorubicin (DOX), because of inflammation in the epithelial cells. We hypothesize that developing a VCAM1-targeted peptide-based (VHPKQHRGGSKGC) fluorescent nanoprobe can detect and visualize the affected heart. In this regard, we prepared a poly(lactic-co-glycolic acid) (PLGA) nanoparticle linked with VCAM1 peptide and rhodamine B (PLGA-VCAM1-RhB). Selective binding and higher accumulation of the PLGA-VCAM1-RhB nanoprobes were detected in DOX-treated human cardiomyocyte cells (HCMs) compared to the untreated cells. For in vivo studies, DOX (5 mg/kg) was injected via the tail vein once in two weeks for 6 weeks (3 injection total). PLGA-VCAM1-RhB and PLGA-RhB were injected via the tail vein after 1 week of the last dose of DOX, and images were taken 4 h after administration. A higher fluorescent signal of PLGA-RhB-VCAM-1 (48.62% ± 12.79%) was observed in DOX-treated animals compared to the untreated control PLGA-RhB (10.61% ± 4.90) within the heart, indicating the specificity and targeting ability of PLGA-VCAM1-RhB to the inflamed tissues. The quantified fluorescence intensity of the homogenized cardiac tissue of PLGA-RhB-VCAM1 showed 156% higher intensity than the healthy control group. We conclude that PLGA-VCAM1-RhB has the potential to bind inflamed cardiac cells, thereby detecting DOX-induced cardiotoxicity and damaged heart at an early stage.
Insights
This study developed a novel fluorescent nanoprobe to detect chemotherapy-induced heart damage early. The probe targets overexpressed VCAM1 in inflamed cardiac tissue, showing promise for monitoring cardiotoxicity.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cardiology
Background:
- Chemotherapy, particularly doxorubicin (DOX), often causes cardiotoxicity, increasing mortality and reducing quality of life.
- Current methods lack feasibility for early detection and monitoring of chemotherapy-induced cardiac damage.
- Vascular cell adhesion molecule 1 (VCAM1) is overexpressed in cardiac tissue due to inflammation from DOX treatment.
Purpose of the Study:
- To develop a VCAM1-targeted fluorescent nanoprobe for early detection and imaging of chemotherapy-induced cardiotoxicity.
- To visualize and quantify the accumulation of the nanoprobe in cardiac tissue affected by DOX treatment.
Main Methods:
- Synthesized poly(lactic-co-glycolic acid) (PLGA) nanoparticles functionalized with a VCAM1-targeting peptide and rhodamine B (PLGA-VCAM1-RhB).
- Evaluated selective binding and accumulation of PLGA-VCAM1-RhB in DOX-treated human cardiomyocyte cells (HCMs) in vitro.
- Administered PLGA-VCAM1-RhB and control PLGA-RhB to DOX-treated and untreated animals in vivo for fluorescence imaging.
Main Results:
- PLGA-VCAM1-RhB showed selective binding and higher accumulation in DOX-treated HCMs compared to untreated cells.
- In vivo imaging revealed significantly higher fluorescent signal (48.62% ± 12.79%) in the hearts of DOX-treated animals using PLGA-VCAM1-RhB compared to controls (10.61% ± 4.90%).
- Quantified fluorescence intensity in homogenized cardiac tissue was 156% higher in the PLGA-VCAM1-RhB group from DOX-treated animals compared to healthy controls.
Conclusions:
- The VCAM1-targeted fluorescent nanoprobe (PLGA-VCAM1-RhB) effectively targets and binds to inflamed cardiac cells.
- This nanoprobe demonstrates significant potential for early-stage detection and visualization of doxorubicin-induced cardiotoxicity.
- The developed technology offers a promising tool for monitoring heart damage in patients undergoing chemotherapy.
More Related Videos
09:48Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017